We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

46 hedge funds and large institutions have $73.3M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

10% more capital invested

Capital invested by funds: $66.8M → $73.3M (+$6.51M)

0% more funds holding

Funds holding: 46 → 46 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

Holders
46
Holders Change
–
Holders Change %
0%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$5.12M
2
AA
AQR Arbitrage
Connecticut
+$979K
3
CCM
CAAS Capital Management
New York
+$947K
4
MF
Magnetar Financial
Illinois
+$867K
5
PAMP
Polar Asset Management Partners
Ontario, Canada
+$455K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$6.1M
2
ACA
Arena Capital Advisors
California
-$959K
3
AMH
Apollo Management Holdings
New York
-$909K
4
FTCM
Fir Tree Capital Management
New York
-$428K
5
EAM
Exos Asset Management
New York
-$103K
Name Holding Trade Value Shares
Change 		Change in
Stake
GCL
1
Glazer Capital LLC
New York
$6.93M +$5.12M +523,267 +283%
Millennium Management
2
Millennium Management
New York
$5.84M -$25K -2,555 -0.4%
PC
3
Periscope Capital
Ontario, Canada
$4.96M – – –
Macquarie Group
4
Macquarie Group
Australia
$4.93M – – –
LA
5
Linden Advisors
New York
$4.87M – – –
Marshall Wace
6
Marshall Wace
United Kingdom
$4.27M – – –
SC
7
Sculptor Capital
New York
$3.46M -$95K -9,711 -3%
SCM
8
Suvretta Capital Management
New York
$2.94M – – –
PMAM
9
Picton Mahoney Asset Management
Ontario, Canada
$2.69M – – –
WP
10
Woodline Partners
California
$2.69M – – –
Bank of America
11
Bank of America
North Carolina
$2.54M – – –
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$2.52M – – –
MI
13
MMCAP International
Cayman Islands
$2.45M – – –
RCM
14
Radcliffe Capital Management
Pennsylvania
$2.09M – – –
AA
15
AQR Arbitrage
Connecticut
$1.96M +$979K +100,000 +100%
KL
16
KIM LLC
Kansas
$1.96M +$1.96M +200,000 New
Alyeska Investment Group
17
Alyeska Investment Group
Illinois
$1.47M – – –
GCM
18
Ghisallo Capital Management
Massachusetts
$1.22M – – –
MCM
19
Moore Capital Management
New York
$1.22M – – –
FTCM
20
Fir Tree Capital Management
New York
$1.04M -$428K -43,700 -29%
State of Wisconsin Investment Board
21
State of Wisconsin Investment Board
Wisconsin
$987K – – –
TCM
22
Tenor Capital Management
New York
$979K – – –
DCM
23
Dupont Capital Management
Delaware
$978K – – –
Hudson Bay Capital Management
24
Hudson Bay Capital Management
Connecticut
$978K – – –
CCM
25
CAAS Capital Management
New York
$947K +$947K +96,710 New
1
2

EBAC Hedge Fund Activity: Q2 2022 in Review

46 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q2 2022, worth a combined $73.3M — up 9.8% from $66.8M a quarter earlier.

Fund positioning in EBAC was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 5 trimmed.

The largest buyer was Glazer Capital LLC, adding an estimated $5.12M. The largest seller was Citadel Advisors, exiting entirely with an estimated $6.1M sold.

  • 46 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $73.3M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q2 2022, up 9.8% quarter-over-quarter.
  • 5 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q2 2022 and 5 closed out, a net change of 0 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q2 2022 was Glazer Capital LLC, an estimated $5.12M added.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q2 2022 was Citadel Advisors, an estimated $6.1M sold.

Based on aggregated 13F filings for Q2 2022.